FDA Advisers Vote to Recommend Merck COVID-19 Pill for Emergency Use Authorization

FDA Advisers Vote to Recommend Merck COVID-19 Pill for Emergency Use Authorization
An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co. Inc. and Ridgeback Biotherapeutics LP. Merck & Co. Inc./Handout via Reuters
Updated:

Outside advisers to the U.S. Food and Drug Administration (FDA) on Tuesday narrowly voted to recommend the agency grant emergency use authorization (EUA) for a drug from Merck and Ridgeback Biotherapeutics to treat COVID-19, called molnupiravir.

Members of the FDA’s Antimicrobial Drugs Advisory Committee voted 13 for and 10 against the EUA for molnupiravir, agreeing with the idea that the drug’s benefits outweigh its potential risks, including potential birth defects if used during pregnancy.

Related Topics